It's Time For a Quick Look at Intercept Pharmaceuticals's Fundamentals.

By Ken Smith • Tuesday, September 26 12:10 • Permanent Link

We're taking a closer look at Intercept Pharmaceuticals today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 79.0% compared to -1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.
Intercept Pharmaceuticals has moved 12.0% over the last year compared to 19.0% for the S&P 500 -- a difference of -7.0%
ICPT has an average analyst rating of hold and is 28.19% away from its mean target price of $14.58 per share
Its trailing 12 month earnings per share (EPS) is $-4.14
Intercept Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -4.5 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $2.05 and its forward P/E ratio is 9.1
ICPT has a Price to Earnings Growth (PEG) ratio of 0.9, which shows the company is very undervalued compared to its earnings growth estimates.
The company has a Price to Book (P/B) ratio of 11.56 in contrast to the S&P 500's average ratio of 2.95
Intercept Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
Intercept Pharmaceuticals has on average reported free cash flows of $-160981333.3 over the last four years, during which time they have grown by an an average of -0.0%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.